Menu

Filtros : "The AAPS Journal" Limpar

Filtros

Refine with date range

  • 1

1 - 3 (3 records)

  • Artigo de periodico

    Doxorubicin stability-indicating method and its main degradation products in vitro toxicity (2025)

    Ultramari, Mariah de Almeida ; Julio, Ariane Rivellis ; Passos, Larissa Souza ; Souza, Alexander Ossanes de ; Silva, Núbia Pereira da ; Freitas, Paloma Nathane Nunes de ; Pinto Junior, Ernani

    Source: The AAPS Journal. Unidades: CENA, ESALQ

    Subjects: FÁRMACOS, PRODUTOS, TOXICOLOGIA

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ULTRAMARI, Mariah de Almeida et al. Doxorubicin stability-indicating method and its main degradation products in vitro toxicity. The AAPS Journal, v. 27, n. 5, p. 1-16, 2025Tradução . . Disponível em: https://doi.org/10.1208/s12248-025-01104-y. Acesso em: 09 fev. 2026.

    • APA

      Ultramari, M. de A., Julio, A. R., Passos, L. S., Souza, A. O. de, Silva, N. P. da, Freitas, P. N. N. de, & Pinto Junior, E. (2025). Doxorubicin stability-indicating method and its main degradation products in vitro toxicity. The AAPS Journal, 27( 5), 1-16. doi:10.1208/s12248-025-01104-y

    • NLM

      Ultramari M de A, Julio AR, Passos LS, Souza AO de, Silva NP da, Freitas PNN de, Pinto Junior E. Doxorubicin stability-indicating method and its main degradation products in vitro toxicity [Internet]. The AAPS Journal. 2025 ; 27( 5): 1-16.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1208/s12248-025-01104-y

    • Vancouver

      Ultramari M de A, Julio AR, Passos LS, Souza AO de, Silva NP da, Freitas PNN de, Pinto Junior E. Doxorubicin stability-indicating method and its main degradation products in vitro toxicity [Internet]. The AAPS Journal. 2025 ; 27( 5): 1-16.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1208/s12248-025-01104-y

  • Artigo de periodico

    Using physiologically based pharmacokinetic modeling to assess the risks of failing bioequivalence criteria: a tale of two ibuprofen products (2020)

    Loisios-Konstantinidis, Ioannis ; Hens, Bart ; Mitra, Amitava; Kim, Sarah; Chiann, Chang ; Cristofoletti, Rodrigo

    Source: The AAPS Journal. Unidade: IME

    Subjects: BIOEQUIVALÊNCIA, FARMACOCINÉTICA, REAMOSTRAGEM BOOTSTRAP

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LOISIOS-KONSTANTINIDIS, Ioannis et al. Using physiologically based pharmacokinetic modeling to assess the risks of failing bioequivalence criteria: a tale of two ibuprofen products. The AAPS Journal, v. 22, n. Artigo 113, p. 1-9, 2020Tradução . . Disponível em: https://doi.org/10.1208/s12248-020-00495-4. Acesso em: 09 fev. 2026.

    • APA

      Loisios-Konstantinidis, I., Hens, B., Mitra, A., Kim, S., Chiann, C., & Cristofoletti, R. (2020). Using physiologically based pharmacokinetic modeling to assess the risks of failing bioequivalence criteria: a tale of two ibuprofen products. The AAPS Journal, 22( Artigo 113), 1-9. doi:10.1208/s12248-020-00495-4

    • NLM

      Loisios-Konstantinidis I, Hens B, Mitra A, Kim S, Chiann C, Cristofoletti R. Using physiologically based pharmacokinetic modeling to assess the risks of failing bioequivalence criteria: a tale of two ibuprofen products [Internet]. The AAPS Journal. 2020 ; 22( Artigo 113): 1-9.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1208/s12248-020-00495-4

    • Vancouver

      Loisios-Konstantinidis I, Hens B, Mitra A, Kim S, Chiann C, Cristofoletti R. Using physiologically based pharmacokinetic modeling to assess the risks of failing bioequivalence criteria: a tale of two ibuprofen products [Internet]. The AAPS Journal. 2020 ; 22( Artigo 113): 1-9.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1208/s12248-020-00495-4

  • Artigo de periodico

    Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac (2017)

    Silva, Carolina de Miranda; Rocha, Adriana; Tozatto, Eduardo; Silva, Lucienir Maria da; Donadi, Eduardo Antônio; Costa, Teresa Dalla; Lanchote, Vera Lúcia; Schmidt, Stephan; Bulitta, Jürgen B.

    Source: The AAPS Journal. Unidades: FCFRP, FMRP

    Subjects: FARMACODINÂMICA, FARMACOCINÉTICA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SILVA, Carolina de Miranda et al. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac. The AAPS Journal, v. 19, n. 6, p. 1814-1825, 2017Tradução . . Disponível em: https://doi.org/10.1208/s12248-017-0138-9. Acesso em: 09 fev. 2026.

    • APA

      Silva, C. de M., Rocha, A., Tozatto, E., Silva, L. M. da, Donadi, E. A., Costa, T. D., et al. (2017). Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac. The AAPS Journal, 19( 6), 1814-1825. doi:10.1208/s12248-017-0138-9

    • NLM

      Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Costa TD, Lanchote VL, Schmidt S, Bulitta JB. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac [Internet]. The AAPS Journal. 2017 ; 19( 6): 1814-1825.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1208/s12248-017-0138-9

    • Vancouver

      Silva C de M, Rocha A, Tozatto E, Silva LM da, Donadi EA, Costa TD, Lanchote VL, Schmidt S, Bulitta JB. Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac [Internet]. The AAPS Journal. 2017 ; 19( 6): 1814-1825.[citado 2026 fev. 09 ] Available from: https://doi.org/10.1208/s12248-017-0138-9
  • 1

1 - 3 (3 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2026